Armata Pharmaceuticals, Inc.
ARMP Healthcare Biotechnology
Armata Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.9 million, down 5.22% from fiscal 2024. In the quarter to June 2026, revenue grew 15.7%, EPS grew 548.9%, free cash flow fell 18.0% and total debt rose 152.4%, each against the same quarter a year earlier.
Follow ARMP
Armata Pharmaceuticals, Inc. (ARMP) EV/Sales
As of 16 October 2026, Armata Pharmaceuticals, Inc. (ARMP) trades at a EV/Sales of 68.8×. Over the past ten years it has ranged from −46.8× (August 2017) to 612× (October 2018); the current reading is higher than 67% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 124× | 445.67% |
| FY2024 | 22.7× | (47.07%) |
| FY2023 | 42.8× | 229.23% |
| FY2022 | 13.0× | (63.56%) |
| FY2021 | 35.7× | (42.56%) |
| FY2020 | 62.2× | 443.43% |
| FY2017 | 11.4× | — |
| FY2016 | −3.4× | — |
| FY2015 | 25.6× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 89.8× | (44.61%) |
| Mar 2026 | 162× | 30.99% |
| Dec 2025 | 124× | 161.13% |
| Sep 2025 | 47.4× | 40.17% |
| 32 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LENZ LENZ Therapeutics, Inc. compare | −5.4× |
| SEER Seer, Inc. compare | −2.9× |
| FHTX Foghorn Therapeutics Inc. compare | −0.5× |
| ENGN enGene Therapeutics Inc compare | n/m |
| NERV Minerva Neurosciences, Inc compare | n/m |
| HURA TuHURA Biosciences, Inc. compare | n/m |
| GNLX Genelux Corporation compare | 8.8× |
| NRXP NRx Pharmaceuticals, Inc. compare | 22.6× |
| ARMP Armata Pharmaceuticals, Inc. | 68.8× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)